ResearcherUniversité Paris CitéActive in the last 2 years
Maxime Barat
Matched on ORCID iD 0000-0002-0360-0875; OpenAlex author ID A5056569937. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 7
- Pancreatic ductal adenocarcinoma in IgG4-related disease. First author DOI 10.1016/j.diii.2026.03.003↗
- Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomography. First author DOI 10.1177/08465371261426959↗
- Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. Co-author DOI 10.1177/08465371221124927↗
- Interobserver Variability and Accuracy of Preoperative CT and MRI in Pancreatic Ductal Adenocarcinoma Size Estimation: A Retrospective Cohort Study. Co-author DOI 10.1177/08465371221137885↗
- Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Co-author DOI 10.3390/cancers14246179↗
- Distal Pancreatectomy with Celiac Axis Resection-with Posterior Ramps Approach-for Locally Advanced Pancreatic Adenocarcinoma with Celiac Trunk Infiltration (M… First author DOI 10.1007/s11605-020-04782-5↗
- Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13133103↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ugo Marchèse · 6 shared papers, 2021–2026 · strength 1.39
- Paper Pancreatic ductal adenocarcinoma in IgG4-related disease. DOI 10.1016/j.diii.2026.03.003↗
- Paper Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomograp… DOI 10.1177/08465371261426959↗
- Paper Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. DOI 10.1177/08465371221124927↗
- Philippe A. Soyer · 5 shared papers, 2021–2026 · strength 0.89
- Paper Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomograp… DOI 10.1177/08465371261426959↗
- Paper Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. DOI 10.1177/08465371221124927↗
- Paper Interobserver Variability and Accuracy of Preoperative CT and MRI in Pancreatic Ductal Adenocarcinoma Size Estimation: … DOI 10.1177/08465371221137885↗
- Romain Coriat · 5 shared papers, 2021–2026 · strength 0.89
- Paper Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomograp… DOI 10.1177/08465371261426959↗
- Paper Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. DOI 10.1177/08465371221124927↗
- Paper Interobserver Variability and Accuracy of Preoperative CT and MRI in Pancreatic Ductal Adenocarcinoma Size Estimation: … DOI 10.1177/08465371221137885↗
- Thị Thùy Linh Nguyễn · 2 shared papers, 2026 · strength 0.77
- Anna Pellat · 3 shared papers, 2022–2026 · strength 0.60
- Paper Differentiating Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma Using Computed Tomograp… DOI 10.1177/08465371261426959↗
- Paper Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances. DOI 10.1177/08465371221124927↗
- Paper Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as… DOI 10.3390/cancers14246179↗
- Marwa Alkatheeri · 1 shared paper, 2026 · strength 0.27
- Jade Fawaz · 1 shared paper, 2021 · strength 0.22
- Sébastien Gaujoux · 1 shared paper, 2021 · strength 0.22
- Christophe Cassinotto · 1 shared paper, 2023 · strength 0.18
- Elliot K. Fishman · 1 shared paper, 2023 · strength 0.18
- Linda Chi Hang Chu · 1 shared paper, 2023 · strength 0.18
- Romain Cocquempot · 1 shared paper, 2023 · strength 0.17
- Victor Mortier · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.